This is the authors' abstract. We don't add key points for this paper.
ABSTARCT Chronic liver disease (CLD) is a major global health burden, with metabolic dysfunction-associated steatotic liver disease (MASLD) as a primary contributor through its promotion of persistent inflammation, fibrotic transformations, and increased cancer risk. Current therapeutic strategies remain inadequate due to poor pharmacokinetics and off-target toxicity, underscoring the need for more targeted and safer treatment options. Macrophages, as key components of the innate immune system, play a central role in liver homeostasis and inflammation, critically shape disease progression and thus represent a compelling therapeutic target. Advances in nanomedicine have led to the development of macrophage membrane–camouflaged nanoparticles (MMNPs), which offer immune-evasive and inflammation-targeting properties conferred by the macrophage membrane. Given the major involvement of macrophages throughout the course of CLD and the superior immunomodulatory properties of their membrane, MMNPs provide a promising and innovative strategy for CLD therapy. This review provides a comprehensive overview of MASLD-associated CLD pathology with a particular focus on the role of macrophages in disease progression. It further explores the characteristics, function-ality, and liver-targeting modifications of MMNPs, highlighting their potential in modulating key pathways to remodel inflammatory environment and reverse liver fibrosis. Finally, existing challenges and future prospects of MMNP-based therapies are discussed, including strategies for enhancing therapeutic efficacy through combination approaches and bioengineering advancements.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ariyathanapong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: